Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cutaneous Tumor Clear all
Completed Phase 1 Interventional

SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

NCT00293488
View directory record Official record
Conditions
Lymphoma
Interventions
polyamine analogue PG11047
Drug
Lead sponsor
Progen Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Jul 22, 2026, 8:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Post Excision/Mohs Scar Laser Resurfacing

NCT02130297
View directory record Official record
Conditions
Skin Cancer
Interventions
Laser Treatment
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Jul 22, 2026, 8:21 PM EDT
Terminated Phase 1 Interventional

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

NCT00003613
View directory record Official record
Conditions
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Interventions
O6-benzylguanine, carmustine, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Jul 22, 2026, 8:21 PM EDT
Completed Early Phase 1 Interventional

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00424242
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jul 22, 2026, 8:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Doxycycline, Temozolomide and Ipilimumab in Melanoma

NCT01590082
View directory record Official record
Conditions
Melanoma
Interventions
Doxycycline, Ipilimumab, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Jul 22, 2026, 8:21 PM EDT
Completed No phase listed Observational

Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1

NCT04941027
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Baltimore, California • Redwood City, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 22, 2026, 8:21 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

NCT05551117
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
Interventions
vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 8:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cemiplimab in AlloSCT/SOT Recipients With CSCC

NCT04339062
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
Interventions
Cemiplimab, Everolimus, Sirolimus, Prednisone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Jul 22, 2026, 8:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

NCT00047060
View directory record Official record
Conditions
Mycosis Fungoides, Sezary Syndrome
Interventions
A matched peripheral donor stem cells, cyclosporine, fludarabine, Campath
Other · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 22, 2026, 8:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

NCT03580382
View directory record Official record
Conditions
Melanoma
Interventions
Trametinib daily Until PD, CDX-3379 (ERBB3 antibody)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Jul 22, 2026, 8:21 PM EDT
Recruiting Phase 3 Interventional

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

NCT06992427
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Gabapentin, Placebo, Chemotheraphy, Radiation Therapy, Analgesic Agent, Biospecimen Collection, Survey Administration
Drug · Radiation · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
200
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 22, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma

NCT00002973
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
melphalan, hyperthermia treatment
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Jul 22, 2026, 8:21 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

NCT06208124
View directory record Official record
Conditions
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
Interventions
IMM-6-415
Drug
Lead sponsor
Immuneering Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jul 22, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00003346
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
acetaminophen, acetylcysteine, carmustine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Jul 22, 2026, 8:21 PM EDT
Recruiting Not applicable Interventional

Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors

NCT07062003
View directory record Official record
Conditions
Metastatic Malignant Skin Neoplasm, Metastatic Malignant Soft Tissue Neoplasm, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Soft Tissue Neoplasm, Skin Neoplasm, Soft Tissue Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Medical Device Usage and Evaluation, Minibeam Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer

NCT04091022
View directory record Official record
Conditions
Non-melanoma Skin Cancer
Interventions
Solaraze and Vaniqa
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 22, 2026, 8:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

NCT02452424
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
Interventions
PLX3397, Pembrolizumab
Drug · Biological
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Jul 22, 2026, 8:21 PM EDT
Active, not recruiting No phase listed Observational

Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

NCT03728842
View directory record Official record
Conditions
Melanoma; Renal Cell Carcinoma
Interventions
Blood collection for laboratory studies, Data collection from medical record
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 22, 2026, 8:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx

NCT05257486
View directory record Official record
Conditions
Non-melanoma Skin Cancer
Interventions
Xoft eBx
Device
Lead sponsor
Xoft, Inc.
Industry
Eligibility
40 Years and older
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Campbell, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jul 22, 2026, 8:21 PM EDT
Completed Phase 3 Interventional

Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter

NCT00006083
View directory record Official record
Conditions
Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific, Veno-occlusive Disease
Interventions
Fragmin, placebo
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 22, 2026, 8:21 PM EDT
Withdrawn Phase 1 Interventional

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

NCT04955262
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C
Biological · Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Jul 22, 2026, 8:21 PM EDT
Terminated No phase listed Observational

SCRI Tissue Testing Registry

NCT00965861
View directory record Official record
Conditions
Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
Interventions
Tissue Registry Study
Other
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Jul 22, 2026, 8:21 PM EDT
Completed Early Phase 1 Interventional

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

NCT04581382
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Pembrolizumab, Radiation Therapy, Therapeutic Exchange Plasma, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jul 22, 2026, 8:21 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

NCT00023790
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Jul 22, 2026, 8:21 PM EDT